Fig. 1.
Fig. 2.
Figu. 3.
Overall Patient Characteristics & Demographic, Non-ICU vs ICU
| Overall | Non-ICU | ICU | |
|---|---|---|---|
| Encounters | 135 | 85 | 50 |
| Patients | 117 | 69 | 48 |
| Demographics | |||
| Mean Age (years) | 58.5 | 56.0 | 61.9 |
| Sex | M, 63, 55% | M, 39 | M, 24 |
| F, 54, 45% | F, 30 | F, 24 | |
| Race | |||
| Black/AA | 89, 66% | 57 | 32 |
| White | 39, 29% | 25 | 14 |
| Other | 7, 5% | 3 | 4 |
| Etiology of AE | |||
| Unknown 63, 47% | Unknown, 48 | ACEi, 27 | |
| ACEi 51, 38% | ACEi, 26 | Unknown, 15 | |
| Other, 13, 10% | Other, 7 | Other, 6 | |
| Hereditary 6, 5% | Hereditary, 4 | Hereditary, 2 | |
| Mean LOS (days) | |||
| Total Hospital LOS | 1.43 2.9 | 0.31 0.69 | 3.37 |
| ICU LOS | -- | -- | 2.40 |
| Treatment | |||
| Histamine/corticosteroid/epinephrine regimen | 120, 78.5% | 72 | 48 |
| Biologic Agent (Icanibant) | 1, 1% | 1 | 0 |
| Other/No treatment | 14, 9.5% | 12 | 2 |
| Otolaryngology (ENT) | |||
| Had ENT Consult | 99, 73.3% | 50, 58% | 49, 98% |
ICU Population: Intubated vs Non-Intubated
| Overall | ICU Non-Intubated | ICU Intubated | |
|---|---|---|---|
| Encounters | 50 | 30 | 20 |
| Patients | 48 | 28 | 20 |
| Demographics | |||
| Mean Age (years) | 61.9 | 63.0 | 60.2 |
| Sex | M, 24, 50% | M, 12 | M, 12 |
| F, 24 | F, 16 | F, 8 | |
| Race | |||
| Black | 32 | 15 | 17 |
| White | 14 | 11 | 3 |
| Other | 4 | 4 | 0 |
| Etiology of AE | |||
| ACEi, 27 | ACEi, 17 | ACEi, 10 | |
| Unknown, 15 | Unknown, 9 | Unknown, 6 | |
| Other, 6 | Other, 3 | Other, 3 | |
| Hereditary, 2 | Hereditary, 1 | Hereditary, 1 | |
| Mean LOS (days) | |||
| Total Hospital LOS | 3.37 | 1.55 | 6.15 |
| ICU LOS | 2.40 | 1.10 | 4.35 |
| Comorbidities | |||
| Airway (OSA, COPD, Asthma) | 12 | 6 | 6 |
| Prior AE episodes or diagnosis of Hereditary AE | 11 | 8 | 3 |
Characteristics of Intubated Patients and Intubation Information
| Intubated Patients | Sex | Age | Race | Angioedema Etiology | Intubation Location | Intubation Timing from Presentation | Intubation rationale | Comorbidities/PMH |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 57 | AA | ACE-I | ED | 2.75 | Dysarthria, tongue edema, floor of mouth edema | HTN, asthma, COPD, breast cancer |
| 2 | F | 77 | AA | ACE-I | ED | 1.5 | Diffuse edema | T2DM, HTN Obesity |
| 3 | M | 51 | AA | ACE-I | ED | 2 | Tongue edema, floor of mouth edema | T2DM |
| 4 | M | 63 | AA | ACE-I | ICU | 7 | Thickness of epiglottis, tongue edema, buccal mucosa edema | Prostate cancer, HTN |
| 5 | M | 37 | AA | ACE-I | ED | 1.3 | Tongue edema, floor of mouth edema, thickness of epiglottis | Obesity, CVA, HTN |
| 6 | M | 68 | AA | ACE-I | ED | 2 | Thickness of epiglottis | HF, AVr, COPD |
| 7 | F | 61 | W | HAE | ED | 3.25 | Diffuse edema, thickness of epiglottis, buccal mucosa edema | Hereditary Angioedema |
| 8 | F | 30 | AA | ACE-I | ICU | 7.5 | dysphagia, dysphonia, uvular swelling | HTN |
| 9 | F | 74 | AA | Methotrexate | ED | 0 | Dysphagia, diffuse edema, dysarthria | SLE, RA, GERD, HTN, DM, HLD, CAD, CKD, OSA, HFpEF |
| 10 | M | 48 | AA | Unk | OSH | 66* | Buccal mucosa edema | HF, CKD III, T2DM, COPD |
| 11 | M | 40 | AA | Unk | ED | 3 | Diffuse edema, intolerance of secretions, thickness of epiglottis | Angioedema, CVA, HTN, T2DM, HLD |
| 12 | F | 72 | AA | Unk | ICU | 1.5 | Diffuse edema | HTN, OSA, HAE, prior trach 2016 |
| 13 | M | 69 | W | Unk | ED | 1.25 | Diffuse edema, intolerance of secretions | ESRD, SUD, Angioedema |
| 14 | M | 67 | AA | Unk | OSH | 2.5 | Diffuse edema, dysarthria | HIV, COPD, Anal Cancer, T2DM, CKD, CAD |
| 15 | M | 68 | W | ACE-I | OSH | - | - | CABG, DM, HLD, Bladder cancer, HTN |
| 16 | F | 55 | AA | ACE-I | OSH | - | - | HTN, G6PD, HLD |
| 17 | M | 57 | AA | ACE-I | OSH | - | - | HTN, Seizures, Gout |
| 18 | M | 65 | AA | ACE-I | OSH | - | - | Renal Transplant, HTN, SUD |
| 19 | F | 84 | AA | Allergy | OSH | - | - | Dementia, HTN |
| 20 | M | 61 | AA | Unk | OSH | - | - | Angioedema, CVA, HTN, T2DM, HLD |